Charles River Laboratories International, Inc. is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development. The Company operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment includes Research Models and Research Model Services. The DSA segment includes Discovery Services and Safety Assessment. The Manufacturing segment includes Microbial Solutions, Avian, Biologics and Contract Manufacturing. The Company also provides a suite of products and services to support the Company's clients' manufacturing activities.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Medical Laboratories & Research
- Sub-Industry: Life Sciences Tools & Services
- Symbol: NYSE:CRL
- CUSIP: 15986410
- Web: www.criver.com
Capitalization:- Market Cap: $4.78347 billion
- Outstanding Shares: 47,639,000
Average Prices:- 50 Day Moving Avg: $92.20
- 200 Day Moving Avg: $85.91
- 52 Week Range: $67.20 - $100.98
P/E:- Trailing P/E Ratio: 29.35
- Foreward P/E Ratio: 17.81
- P/E Growth: 1.75
Sales & Book Value:- Annual Revenue: $1.77 billion
- Price / Sales: 2.70
- Book Value: $18.40 per share
- Price / Book: 5.45
Profitability:- EBIDTA: $423.96 million
- Net Margins: 9.28%
- Return on Equity: 27.46%
- Return on Assets: 8.66%
Debt:- Debt-to-Equity Ratio: 1.33%
- Current Ratio: 1.83%
- Quick Ratio: 1.57%
Misc:- Average Volume: 350,034 shs.
- Beta: 1
- Short Ratio: 5.63
Frequently Asked Questions for Charles River Laboratories International (NYSE:CRL)
What is Charles River Laboratories International's stock symbol?
Charles River Laboratories International trades on the New York Stock Exchange (NYSE) under the ticker symbol "CRL."
How will Charles River Laboratories International's stock buyback program work?
Charles River Laboratories International declared that its board has approved a stock repurchase plan on Sunday, June 4th 2017, which allows the company to repurchase $150,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization allows the company to buy shares of its stock through open market purchases. Shares repurchase plans are typically a sign that the company's board of directors believes its stock is undervalued.
How were Charles River Laboratories International's earnings last quarter?
Charles River Laboratories International, Inc. (NYSE:CRL) released its earnings results on Wednesday, May, 10th. The company reported $1.29 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $1.14 by $0.15. The company had revenue of $445.80 million for the quarter, compared to the consensus estimate of $437.04 million. Charles River Laboratories International had a return on equity of 27.46% and a net margin of 9.28%. The firm's quarterly revenue was up 25.6% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.98 EPS. View Charles River Laboratories International's Earnings History.
When will Charles River Laboratories International make its next earnings announcement?
What guidance has Charles River Laboratories International issued on next quarter's earnings?
Charles River Laboratories International updated its FY17 earnings guidance on Wednesday, May, 10th. The company provided earnings per share (EPS) guidance of $5.00-5.15 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $5.06. The company issued revenue guidance of +7.5-9% to ~$1.81-1.83 billion, compared to the consensus revenue estimate of $1.83 billion.
Where is Charles River Laboratories International's stock going? Where will Charles River Laboratories International's stock price be in 2017?
7 brokers have issued 1-year price objectives for Charles River Laboratories International's shares. Their forecasts range from $77.00 to $106.00. On average, they anticipate Charles River Laboratories International's stock price to reach $93.07 in the next year. View Analyst Ratings for Charles River Laboratories International.
What are analysts saying about Charles River Laboratories International stock?
Here are some recent quotes from research analysts about Charles River Laboratories International stock:
- 1. Jefferies Group LLC analysts commented, "4Q results far outpaced consensus revenue/EPS driven by strength across the 3 segments. Guidance bracketed consensus, lower than us (as expected). We point to margin expansion (with continued price) and capital deployment as upside sources. Strong Discovery and Early Development demand (see our research pointing to funding shifts to Early Dev) should support high single digit organic growth." (2/15/2017)
- 2. According to Zacks Investment Research, "Charles River Laboratories is a leading provider of critical research tools and integrated support services that enable innovative and efficient drug discovery and development. Charles River is the global leader in providing the animal research models required in research and development for new drugs, devices and therapies and has been in this business for more than 50 years. " (11/4/2016)
Who are some of Charles River Laboratories International's key competitors?
Some companies that are related to Charles River Laboratories International include Teleflex Incorporated (TFX), Seattle Genetics (SGEN), Alkermes PLC (ALKS), WellCare Health Plans (WCG), TESARO (TSRO), Qiagen N.V. (QGEN), Alnylam Pharmaceuticals (ALNY), VCA (WOOF), West Pharmaceutical Services (WST), Exelixis (EXEL), William Demant Holdings (WILYY), STERIS PLC (STE), Dr. Reddy's Laboratories Ltd (RDY), DexCom (DXCM), Ionis Pharmaceuticals (IONS), Bio-Rad Laboratories (BIO), BIOVERATIV INC (BIVV) and ABIOMED (ABMD).
Who are Charles River Laboratories International's key executives?
Charles River Laboratories International's management team includes the folowing people:
- James C. Foster, Chairman of the Board, President, Chief Executive Officer
- David R. Smith, Chief Financial Officer, Corporate Executive Vice President
- David P. Johst, Corporate Executive Vice President - Human Resources, Chief Administrative Officer, General Counsel
- William D. Barbo, Corporate Executive Vice President and Chief Commercial Officer
- Davide A. Molho, Corporate Executive Vice President & President, Global Research Models & Services, Safety Assessment and Biologics
- Michael Gunnar Knell, Corporate Senior Vice President, Chief Accounting Officer
- George M. Milne Jr., Ph.D., Lead Independent Director
- Robert J. Bertolini CPA, Independent Director
- Stephen D. Chubb, Independent Director
- Deborah Turner Kochevar Ph.D., Independent Director
Who owns Charles River Laboratories International stock?
Charles River Laboratories International's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (10.63%), BlackRock Inc. (8.12%), FMR LLC (5.25%), Ariel Investments LLC (4.35%), State Street Corp (2.61%) and AQR Capital Management LLC (2.32%). Company insiders that own Charles River Laboratories International stock include C Richard Reese, David P Johst, David Ross Smith, Davide Molho, George M Milne Jr, George Massaro, James C Foster, John J Crowley, Nancy Gillett, Richard F Wallman, Robert J Bertolini, Stephen D Chubb, Thomas F Ackerman and William D Barbo. View Institutional Ownership Trends for Charles River Laboratories International.
Who sold Charles River Laboratories International stock? Who is selling Charles River Laboratories International stock?
Charles River Laboratories International's stock was sold by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., First Trust Advisors LP, Redmile Group LLC, Monarch Partners Asset Management LLC, Russell Investments Group Ltd., Hodges Capital Management Inc., Putnam FL Investment Management Co. and Chartwell Investment Partners LLC. Company insiders that have sold Charles River Laboratories International stock in the last year include C Richard Reese, David P Johst, David Ross Smith, Davide Molho, George Massaro, James C Foster, Richard F Wallman, Robert J Bertolini, Stephen D Chubb and William D Barbo. View Insider Buying and Selling for Charles River Laboratories International.
Who bought Charles River Laboratories International stock? Who is buying Charles River Laboratories International stock?
Charles River Laboratories International's stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., FMR LLC, Ariel Investments LLC, MARSHALL WACE ASIA Ltd, Marshall Wace North America L.P., Morgan Stanley, Eagle Asset Management Inc. and Vanguard Group Inc.. View Insider Buying and Selling for Charles River Laboratories International.
How do I buy Charles River Laboratories International stock?
Shares of Charles River Laboratories International can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Charles River Laboratories International's stock price today?
One share of Charles River Laboratories International stock can currently be purchased for approximately $100.29.
MarketBeat Community Rating for Charles River Laboratories International (NYSE CRL)MarketBeat's community ratings are surveys of what our community members think about Charles River Laboratories International and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Charles River Laboratories International (NYSE:CRL) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 4 Hold Ratings, 3 Buy Ratings |
| Consensus Rating: | Hold (Score: 2.43) |
| Consensus Price Target: | $93.07 (7.20% downside) |
Analysts' Ratings History for Charles River Laboratories International (NYSE:CRL)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 6/14/2017 | Jefferies Group LLC | Reiterated Rating | Buy | | Low |  |
| 6/6/2017 | Credit Suisse Group | Reiterated Rating | Neutral | $89.00 -> $95.00 | Low | |
| 5/13/2017 | Barclays PLC | Set Price Target | Hold | $90.00 | Low | |
| 5/11/2017 | Citigroup Inc. | Reiterated Rating | Neutral | $90.00 -> $104.00 | Low | |
| 1/4/2017 | Evercore ISI | Upgrade | Hold -> Buy | $86.50 | N/A | |
| 12/16/2016 | Goldman Sachs Group, Inc. (The) | Upgrade | Sell -> Neutral | $75.00 -> $77.00 | N/A | |
| 11/18/2016 | Bank of America Corporation | Set Price Target | Buy | $93.00 | N/A | |
| 5/22/2016 | KeyCorp | Reiterated Rating | Hold | $77.00 | N/A | |
| 4/26/2016 | Gabelli | Initiated Coverage | Buy | $96.00 | N/A | |
| 2/11/2016 | Deutsche Bank AG | Reiterated Rating | Hold | $85.00 -> $82.00 | N/A | |
| 1/8/2016 | Robert W. Baird | Boost Price Target | Outperform | $86.00 -> $92.00 | N/A | |
| 1/7/2016 | Wells Fargo & Company | Upgrade | Market Perform -> Outperform | | N/A | |
| 8/28/2015 | William Blair | Reiterated Rating | Outperform | | N/A | |
| 7/10/2015 | Morgan Stanley | Reiterated Rating | Equal Weight | $65.00 -> $68.00 | N/A | |
(Data available from 6/24/2015 forward)
Earnings History for Charles River Laboratories International (NYSE:CRL)Earnings History by Quarter for Charles River Laboratories International (NYSE CRL)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 8/1/2017 | | | | | | | | |
| 5/10/2017 | Q1 2017 | $1.14 | $1.29 | $437.04 million | $445.80 million | View | N/A | |
| 2/14/2017 | Q416 | $1.11 | $1.21 | $441.64 million | $466.80 million | View | Listen | |
| 11/2/2016 | Q316 | $1.13 | $1.18 | $291.20 million | $425.70 million | View | Listen | |
| 8/3/2016 | Q216 | $1.10 | $1.20 | $425.05 million | $434.10 million | View | Listen | |
| 5/4/2016 | Q116 | $0.90 | $0.98 | $354.92 million | $354.90 million | View | Listen | |
| 2/10/2016 | Q415 | $0.94 | $1.00 | $349.20 million | $353.90 million | View | Listen | |
| 11/4/2015 | Q315 | $0.94 | $1.03 | $340.09 million | $349.50 million | View | Listen | |
| 7/30/2015 | Q215 | $0.97 | $0.96 | $338.30 million | $339.60 million | View | Listen | |
| 4/29/2015 | Q115 | $0.82 | $0.79 | $324.00 million | $320.40 million | View | Listen | |
| 2/10/2015 | Q414 | $0.71 | $0.81 | $318.73 million | $329.50 million | View | Listen | |
| 10/29/2014 | Q314 | $0.80 | $0.86 | $326.70 million | $327.60 million | View | Listen | |
| 8/6/2014 | Q214 | $0.82 | $0.97 | $327.96 million | $341.18 million | View | Listen | |
| 4/30/2014 | Q114 | $0.74 | $0.82 | $302.08 million | $299.40 million | View | Listen | |
| 2/12/2014 | Q413 | $0.68 | $0.73 | $289.56 million | $289.20 million | View | Listen | |
| 10/30/2013 | Q313 | $0.70 | $0.79 | $290.28 million | $292.10 million | View | Listen | |
| 7/31/2013 | Q2 2013 | $0.71 | $0.73 | $293.77 million | $294.40 million | View | Listen | |
| 5/1/2013 | Q1 2013 | $0.71 | $0.69 | $294.53 million | $291.20 million | View | Listen | |
| 2/13/2013 | Q4 2012 | $0.60 | $0.64 | $280.81 million | $280.10 million | View | Listen | |
| 10/30/2012 | | $0.62 | $0.65 | | | View | N/A | |
| 8/7/2012 | | $0.66 | $0.75 | | | View | N/A | |
| 5/2/2012 | | $0.65 | $0.70 | | | View | N/A | |
| 2/13/2012 | | $0.56 | $0.69 | | | View | N/A | |
| 11/1/2011 | | $0.58 | $0.57 | | | View | N/A | |
| 8/2/2011 | | $0.60 | $0.70 | | | View | N/A | |
| 5/3/2011 | | $0.55 | $0.61 | | | View | N/A | |
| 2/8/2011 | | $0.50 | $0.60 | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Charles River Laboratories International (NYSE:CRL)2017 EPS Consensus Estimate: $4.94
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 5 | $1.07 | $1.16 | $1.13 |
| Q2 2017 | 5 | $1.21 | $1.29 | $1.23 |
| Q3 2017 | 5 | $1.25 | $1.26 | $1.25 |
| Q4 2017 | 5 | $1.31 | $1.35 | $1.33 |
| Q1 2018 | 1 | $1.35 | $1.35 | $1.35 |
(Data provided by Zacks Investment Research)
Dividend History for Charles River Laboratories International (NYSE:CRL)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Charles River Laboratories International (NYSE:CRL)Insider Ownership Percentage: 2.20%
Institutional Ownership Percentage: 98.06%
Insider Trades by Quarter for Charles River Laboratories International (NYSE:CRL)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 6/22/2017 | Davide Molho | Insider | Sell | 10,948 | $100.00 | $1,094,800.00 | |
| 6/22/2017 | James C Foster | Chairman | Sell | 43,154 | $100.00 | $4,315,400.00 | |
| 6/8/2017 | David Ross Smith | Insider | Sell | 945 | $95.00 | $89,775.00 | |
| 5/26/2017 | Davide Molho | Insider | Sell | 10,976 | $92.84 | $1,019,011.84 | |
| 5/12/2017 | George Massaro | Director | Sell | 1,130 | $88.30 | $99,779.00 | |
| 3/16/2017 | Davide Molho | Insider | Sell | 11,717 | $90.00 | $1,054,530.00 | |
| 3/10/2017 | David P Johst | Insider | Sell | 34,593 | $89.06 | $3,080,852.58 | |
| 3/6/2017 | William D Barbo | Insider | Sell | 1,900 | $87.90 | $167,010.00 | |
| 3/3/2017 | David Ross Smith | EVP | Sell | 3,890 | $88.12 | $342,786.80 | |
| 3/1/2017 | Robert J Bertolini | Director | Sell | 5,255 | $87.53 | $459,970.15 | |
| 2/28/2017 | James C Foster | Chairman | Sell | 4,910 | $87.09 | $427,611.90 | |
| 2/22/2017 | James C Foster | Chairman | Sell | 9,717 | $87.64 | $851,597.88 | |
| 1/30/2017 | David P Johst | Insider | Sell | 13,950 | $78.00 | $1,088,100.00 | |
| 12/2/2016 | Stephen D Chubb | Director | Sell | 4,564 | $71.57 | $326,645.48 | |
| 11/28/2016 | C Richard Reese | Director | Sell | 4,539 | $71.93 | $326,490.27 | |
| 8/30/2016 | Davide Molho | Insider | Sell | 7,877 | $84.10 | $662,455.70 | |
| 8/5/2016 | James C Foster | Chairman | Sell | 18,351 | $85.63 | $1,571,396.13 | |
| 7/29/2016 | Richard F Wallman | Director | Sell | 7,740 | $88.00 | $681,120.00 | |
| 7/1/2016 | George Massaro | Director | Sell | 3,740 | $83.09 | $310,756.60 | |
| 5/24/2016 | John J Crowley | CAO | Sell | 1,913 | $85.00 | $162,605.00 | |
| 5/13/2016 | Richard F Wallman | Director | Sell | 1,970 | $82.32 | $162,170.40 | |
| 5/10/2016 | Richard F Wallman | Director | Sell | 11,990 | $84.00 | $1,007,160.00 | |
| 5/9/2016 | George Massaro | Director | Sell | 985 | $82.17 | $80,937.45 | |
| 5/6/2016 | Richard F Wallman | Director | Sell | 2,720 | $81.00 | $220,320.00 | |
| 4/6/2016 | Davide Molho | VP | Sell | 30,667 | $80.00 | $2,453,360.00 | |
| 3/2/2016 | Nancy Gillett | VP | Sell | 7,015 | $75.00 | $526,125.00 | |
| 2/29/2016 | Nancy Gillett | VP | Sell | 3,646 | $73.50 | $267,981.00 | |
| 2/25/2016 | David P Johst | VP | Sell | 34,075 | $73.02 | $2,488,156.50 | |
| 2/24/2016 | James C Foster | CEO | Sell | 3,873 | $70.40 | $272,659.20 | |
| 2/23/2016 | George M Milne Jr | Director | Sell | 10,440 | $73.02 | $762,328.80 | |
| 2/22/2016 | James C Foster | CEO | Sell | 9,831 | $73.12 | $718,842.72 | |
| 2/12/2016 | C Richard Reese | Director | Sell | 4,228 | $71.48 | $302,217.44 | |
| 2/12/2016 | Nancy Gillett | VP | Sell | 6,750 | $71.90 | $485,325.00 | |
| 2/1/2016 | Stephen D Chubb | Director | Sell | 2,000 | $74.76 | $149,520.00 | |
| 12/17/2015 | George Massaro | Director | Sell | 7,740 | $80.00 | $619,200.00 | |
| 12/17/2015 | Thomas F. Ackerman | insider | Sell | 10,000 | $80.00 | $800,000.00 | |
| 11/19/2015 | Thomas F. Ackerman | insider | Sell | 10,000 | $75.00 | $750,000.00 | |
| 11/4/2015 | Thomas F. Ackerman | insider | Sell | 21,612 | $70.01 | $1,513,056.12 | |
| 11/2/2015 | Stephen D Chubb | Director | Sell | 2,000 | $66.57 | $133,140.00 | |
| 8/17/2015 | Thomas F Ackerman | Insider | Sell | 5,000 | $75.53 | $377,650.00 | |
| 5/15/2015 | Thomas F Ackerman | CFO | Sell | 3,900 | $70.51 | $274,989.00 | |
| 5/7/2015 | George Massaro | Director | Sell | 1,360 | $70.21 | $95,485.60 | |
| 3/3/2015 | Stephen D Chubb | Director | Sell | 2,000 | $75.52 | $151,040.00 | |
| 3/2/2015 | Deborah Turner Kochevar | Director | Sell | 2,600 | $76.59 | $199,134.00 | |
| 3/2/2015 | James C Foster | CEO | Sell | 2,036 | $76.93 | $156,629.48 | |
| 3/2/2015 | Nancy Gillett | VP | Sell | 4,379 | $76.72 | $335,956.88 | |
| 2/27/2015 | Nancy Gillett | VP | Sell | 2,772 | $76.95 | $213,305.40 | |
| 2/25/2015 | James C Foster | CEO | Sell | 4,621 | $75.96 | $351,011.16 | |
| 2/25/2015 | Nancy Gillett | VP | Sell | 5,015 | $76.12 | $381,741.80 | |
| 2/24/2015 | James C Foster | CEO | Sell | 4,800 | $75.70 | $363,360.00 | |
| 2/24/2015 | Jorg Geller | VP | Sell | 12,061 | $76.17 | $918,686.37 | |
| 2/23/2015 | James C Foster | CEO | Sell | 8,423 | $76.56 | $644,864.88 | |
| 2/23/2015 | Jorg Geller | VP | Sell | 7,041 | $76.59 | $539,270.19 | |
| 2/20/2015 | George M Milne Jr | Director | Sell | 6,000 | $75.87 | $455,220.00 | |
| 2/19/2015 | James C Foster | CEO | Sell | 9,671 | $75.00 | $725,325.00 | |
| 2/18/2015 | Stephen D Chubb | Director | Sell | 5,011 | $73.97 | $370,663.67 | |
| 2/17/2015 | Jorg Geller | VP | Sell | 14,430 | $73.54 | $1,061,182.20 | |
| 2/17/2015 | Thomas F Ackerman | CFO | Sell | 4,400 | $73.50 | $323,400.00 | |
| 2/13/2015 | Davide Molho | VP | Sell | 19,075 | $74.00 | $1,411,550.00 | |
| 2/12/2015 | Jorg Geller | VP | Sell | 8,458 | $73.68 | $623,185.44 | |
| 1/26/2015 | Thomas F Ackerman | CFO | Sell | 10,000 | $70.00 | $700,000.00 | |
| 1/8/2015 | David P Johst | VP | Sell | 4,737 | $67.00 | $317,379.00 | |
| 1/7/2015 | David P Johst | VP | Sell | 26,100 | $65.00 | $1,696,500.00 | |
| 12/1/2014 | Stephen D Chubb | Director | Sell | 2,000 | $64.44 | $128,880.00 | |
| 11/28/2014 | David P Johst | VP | Sell | 6,982 | $65.34 | $456,203.88 | |
| 11/17/2014 | Thomas F Ackerman | CFO | Sell | 10,000 | $63.70 | $637,000.00 | |
| 11/14/2014 | Jorg Geller | VP | Sell | 5,610 | $63.57 | $356,627.70 | |
| 11/6/2014 | C Richard Reese | Director | Sell | 5,849 | $63.39 | $370,768.11 | |
| 11/4/2014 | John J Crowley | CAO | Sell | 1,000 | $64.00 | $64,000.00 | |
| 11/3/2014 | Davide Molho | VP | Sell | 16,402 | $64.54 | $1,058,585.08 | |
| 11/3/2014 | George Massaro | Director | Sell | 16,710 | $65.00 | $1,086,150.00 | |
| 11/3/2014 | Thomas F Ackerman | CFO | Sell | 36,100 | $65.00 | $2,346,500.00 | |
| 10/30/2014 | Nancy Gillett | VP | Sell | 1,069 | $65.00 | $69,485.00 | |
| 10/28/2014 | David P Johst | VP | Sell | 74,780 | $64.00 | $4,785,920.00 | |
| 10/3/2014 | James C Foster | CEO | Sell | 136,647 | $62.00 | $8,472,114.00 | |
| 9/29/2014 | Thomas F Ackerman | CFO | Sell | 5,000 | $60.00 | $300,000.00 | |
| 9/4/2014 | Davide Molho | VP | Sell | 4,900 | $61.34 | $300,566.00 | |
| 9/2/2014 | Stephen D Chubb | Director | Sell | 2,000 | $59.18 | $118,360.00 | |
| 8/26/2014 | George Massaro | Director | Sell | 10,440 | $60.00 | $626,400.00 | |
| 8/18/2014 | Thomas F Ackerman | CFO | Sell | 23,156 | $59.25 | $1,371,993.00 | |
| 8/12/2014 | Richard F Wallman | Director | Sell | 3,240 | $58.20 | $188,568.00 | |
| 6/2/2014 | Stephen D Chubb | Director | Sell | 2,000 | $52.93 | $105,860.00 | |
| 5/22/2014 | Deborah Turner Kochevar | Director | Sell | 3,100 | $53.30 | $165,230.00 | |
| 5/8/2014 | George Massaro | Director | Sell | 1,620 | $52.70 | $85,374.00 | |
| 5/5/2014 | Thomas Ackerman | CFO | Sell | 5,430 | $50.76 | $275,626.80 | |
| 3/7/2014 | Nancy Gillett | VP | Sell | 10,110 | $58.36 | $590,019.60 | |
| 3/4/2014 | Nancy Gillett | VP | Sell | 13,650 | $58.98 | $805,077.00 | |
| 3/3/2014 | Stephen Chubb | Director | Sell | 2,000 | $58.70 | $117,400.00 | |
| 2/28/2014 | Jorg Geller | VP | Sell | 7,486 | $59.41 | $444,743.26 | |
| 2/27/2014 | Nancy Gillett | VP | Sell | 4,000 | $60.00 | $240,000.00 | |
| 2/25/2014 | Jorg Geller | VP | Sell | 3,188 | $58.49 | $186,466.12 | |
| 2/20/2014 | Nancy Gillett | VP | Sell | 4,000 | $58.96 | $235,840.00 | |
| 2/19/2014 | Stephen Chubb | Director | Sell | 5,198 | $58.35 | $303,303.30 | |
| 2/18/2014 | Thomas Ackerman | CFO | Sell | 14,000 | $58.05 | $812,700.00 | |
| 1/13/2014 | David Johst | VP | Sell | 19,750 | $58.00 | $1,145,500.00 | |
| 1/7/2014 | George Massaro | Director | Sell | 5,750 | $54.00 | $310,500.00 | |
| 12/20/2013 | Thomas Ackerman | CFO | Sell | 5,000 | $52.72 | $263,600.00 | |
| 12/4/2013 | Jorg Geller | VP | Sell | 7,200 | $51.93 | $373,896.00 | |
| 12/2/2013 | Stephen Chubb | Director | Sell | 2,000 | $51.92 | $103,840.00 | |
| 9/16/2013 | George Massaro | Director | Sell | 5,958 | $47.38 | $282,290.04 | |
| 9/9/2013 | James C Foster | CEO | Sell | 174,479 | $47.00 | $8,200,513.00 | |
| 9/4/2013 | Thomas F Ackerman | CFO | Sell | 6,100 | $46.13 | $281,393.00 | |
| 9/3/2013 | Stephen Chubb | Director | Sell | 2,000 | $46.49 | $92,980.00 | |
| 8/29/2013 | James Foster | CEO | Sell | 40,983 | $47.00 | $1,926,201.00 | |
| 8/22/2013 | Davide Molho | VP | Sell | 6,500 | $47.93 | $311,545.00 | |
| 8/20/2013 | Stephen Chubb | Director | Sell | 4,000 | $47.46 | $189,840.00 | |
| 8/5/2013 | Jorg Geller | VP | Sell | 3,025 | $46.38 | $140,299.50 | |
| 8/5/2013 | Richard Wallman | Director | Sell | 1,500 | $45.95 | $68,925.00 | |
| 8/2/2013 | Davide Molho | VP | Sell | 4,100 | $45.89 | $188,149.00 | |
| 8/2/2013 | Deborah Turner Kochevar | Director | Sell | 4,447 | $46.02 | $204,650.94 | |
| 8/2/2013 | Thomas Ackerman | CFO | Sell | 26,250 | $46.03 | $1,208,287.50 | |
| 6/3/2013 | Thomas F Ackerman | CFO | Sell | 4,000 | $42.40 | $169,600.00 | |
| 5/14/2013 | James C Foster | CEO | Sell | 113,810 | $45.00 | $5,121,450.00 | |
| 5/10/2013 | George Massaro | Director | Sell | 2,020 | $44.09 | $89,061.80 | |
| 3/13/2013 | David P Johst | VP | Sell | 17,038 | $45.00 | $766,710.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Charles River Laboratories International (NYSE:CRL)
Latest Headlines for Charles River Laboratories International (NYSE:CRL)
| Source: |
|
| Date | Headline |
|---|
 | Charles River Laboratories International, Inc. (CRL) Chairman James C. Foster Sells 43,154 Shares
www.americanbankingnews.com - June 23 at 5:02 PM |
| Davide Molho Sells 10,948 Shares of Charles River Laboratories International, Inc. (CRL) Stock
www.americanbankingnews.com - June 23 at 1:35 PM |
| $1.22 Earnings Per Share Expected for Charles River Laboratories International, Inc. (CRL) This Quarter
www.americanbankingnews.com - June 23 at 7:58 AM |
| Charles River Laboratories International, Inc. (CRL) Upgraded to Strong-Buy by BidaskClub
www.americanbankingnews.com - June 20 at 8:44 PM |
| Charles River Laboratories International, Inc. (CRL) Receives "Buy" Rating from Jefferies Group LLC
www.americanbankingnews.com - June 14 at 7:56 AM |
| Insider Selling: Charles River Laboratories Intl. Inc (CRL) Insider Sells 945 Shares of Stock
www.americanbankingnews.com - June 9 at 1:34 PM |
| Charles River Laboratories Intl. Inc (CRL) to Post Q2 2017 Earnings of $1.23 Per Share, First Analysis Forecasts
www.americanbankingnews.com - June 7 at 8:16 AM |
| Charles River Laboratories Intl. Inc (CRL) Earns "Neutral" Rating from Credit Suisse Group AG
www.americanbankingnews.com - June 6 at 3:36 PM |
| Charles River Laboratories Intl. Inc (CRL) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - June 6 at 10:33 AM |
 | Charles River Laboratories to Present at Jefferies Global Healthcare Conference
finance.yahoo.com - June 5 at 9:32 PM |
| Charles River Laboratories Intl. (CRL) to Repurchase $150.00 million in Outstanding Shares
www.americanbankingnews.com - June 4 at 11:28 AM |
| ETFs with exposure to Charles River Laboratories International, Inc. : June 1, 2017
finance.yahoo.com - June 1 at 5:08 PM |
| $460.02 Million in Sales Expected for Charles River Laboratories Intl. Inc (CRL) This Quarter
www.americanbankingnews.com - June 1 at 1:20 PM |
| Davide Molho Sells 10,976 Shares of Charles River Laboratories Intl. Inc (CRL) Stock
www.americanbankingnews.com - May 31 at 7:28 AM |
 | Eisai and Charles River Laboratories Announce Extension of Integrated Drug Discovery Partnership
www.finanznachrichten.de - May 30 at 4:28 PM |
| $1.23 Earnings Per Share Expected for Charles River Laboratories Intl. Inc (CRL) This Quarter
www.americanbankingnews.com - May 30 at 9:58 AM |
| Charles River Labs Re-Enters Buy Zone; Gets Stock Rating Upgrade
finance.yahoo.com - May 25 at 6:03 PM |
| Today's Bell Ringer, May 23, 2017
finance.yahoo.com - May 23 at 12:41 PM |
| Opening Bell, May 23, 2017
finance.yahoo.com - May 23 at 12:41 PM |
 | Charles River Laboratories International (CRL) Presents At Bank of America Merrill Lynch 2017 Health Care Conference - Slideshow
seekingalpha.com - May 22 at 4:19 PM |
| ETFs with exposure to Charles River Laboratories International, Inc. : May 16, 2017
finance.yahoo.com - May 16 at 4:30 PM |
| Charles River Laboratories Announces Updates to Oncology Business
finance.yahoo.com - May 16 at 12:15 PM |
| George Massaro Sells 1,130 Shares of Charles River Laboratories Intl. Inc (CRL) Stock
www.americanbankingnews.com - May 15 at 4:22 PM |
| Charles River Laboratories International, Inc. :CRL-US: Earnings Analysis: Q1, 2017 By the Numbers : May 15, 2017
finance.yahoo.com - May 15 at 12:02 PM |
| FY2017 Earnings Forecast for Charles River Laboratories Intl. Inc (CRL) Issued By William Blair
www.americanbankingnews.com - May 15 at 8:48 AM |
| FY2017 EPS Estimates for Charles River Laboratories Intl. Inc Increased by Analyst (CRL)
www.americanbankingnews.com - May 15 at 8:48 AM |
| Charles River Laboratories Intl. Inc Expected to Post FY2017 Earnings of $5.09 Per Share (CRL)
www.americanbankingnews.com - May 15 at 8:48 AM |
| Q2 2017 Earnings Estimate for Charles River Laboratories Intl. Inc (CRL) Issued By SunTrust Banks
www.americanbankingnews.com - May 15 at 7:58 AM |
| Barclays PLC Analysts Give Charles River Laboratories Intl. Inc (CRL) a $90.00 Price Target
www.americanbankingnews.com - May 15 at 12:34 AM |
| Gabelli Weighs in on Charles River Laboratories Intl. Inc's FY2021 Earnings (CRL)
www.americanbankingnews.com - May 12 at 6:56 PM |
| Charles River Laboratories International, Inc. breached its 50 day moving average in a Bearish Manner : CRL-US : May 12, 2017
finance.yahoo.com - May 12 at 5:02 PM |
| Charles River shareholders reject PETA proposal on monkey research
finance.yahoo.com - May 12 at 5:02 PM |
| Charles River Laboratories Intl. Inc (CRL) to Post Q2 2017 Earnings of $1.21 Per Share, Jefferies Group Forecasts
www.americanbankingnews.com - May 12 at 10:40 AM |
| Q2 2017 Earnings Forecast for Charles River Laboratories Intl. Inc (CRL) Issued By William Blair
www.americanbankingnews.com - May 12 at 10:40 AM |
| Charles River Laboratories Intl. Inc (CRL) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - May 12 at 10:37 AM |
| Jefferies Group LLC Reaffirms "Buy" Rating for Charles River Laboratories Intl. Inc (CRL)
www.americanbankingnews.com - May 11 at 8:32 PM |
| Charles River Laboratories Intl.'s (CRL) Neutral Rating Reaffirmed at Citigroup Inc
www.americanbankingnews.com - May 11 at 8:32 PM |
| Edited Transcript of CRL earnings conference call or presentation 10-May-17 12:30pm GMT
finance.yahoo.com - May 10 at 9:43 PM |
| Charles River Laboratories International (CRL) Q1 2017 Results - Earnings Call Transcript
seekingalpha.com - May 10 at 4:40 PM |
| Charles River Laboratories Intl. Inc (CRL) Releases Earnings Results
www.americanbankingnews.com - May 10 at 2:26 PM |
| Charles River Laboratories Intl. Inc (CRL) Releases FY17 Earnings Guidance
www.americanbankingnews.com - May 10 at 9:02 AM |
| Charles River Laboratories Announces First-Quarter 2017 Results from Continuing Operations
finance.yahoo.com - May 10 at 8:09 AM |
 | Charles River beats Street 1Q forecasts
marketbeat.com - May 10 at 7:28 AM |
| $438.08 Million in Sales Expected for Charles River Laboratories Intl. Inc (CRL) This Quarter
www.americanbankingnews.com - May 6 at 9:27 AM |
| 4 Medical Stocks That Could Be Big Winners Next Week
finance.yahoo.com - May 5 at 9:44 PM |
| Zacks: Brokerages Anticipate Charles River Laboratories Intl. Inc (CRL) Will Announce Earnings of $1.14 Per Share
www.americanbankingnews.com - May 4 at 11:23 AM |
| Charles River Laboratories Intl. (CRL) Receiving Somewhat Critical Media Coverage, Report Finds
www.americanbankingnews.com - May 1 at 4:30 PM |
| Somewhat Favorable Press Coverage Very Unlikely to Impact Charles River Laboratories Intl. (CRL) Stock Price
www.americanbankingnews.com - April 28 at 10:14 PM |
| Charles River Laboratories International, Inc. breached its 50 day moving average in a Bearish Manner : CRL-US : April 26, 2017
finance.yahoo.com - April 27 at 2:11 AM |
| Charles River Laboratories Intl. (CRL) Receiving Somewhat Favorable Media Coverage, AlphaOne Reports
www.americanbankingnews.com - April 25 at 5:14 PM |
Charles River Laboratories International (CRL) Chart for Saturday, June, 24, 2017
